Daewoong Participates in CPHI Worldwide 2022... Seeking Partners for 'Pexuclu', 'Enblo', and 'Nabota'

Overview of Daewoong Pharmaceutical booth installed at 'CPHI Worldwide 2022' event in Frankfurt, Germany (Photo by Daewoong Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical announced on the 1st that it will participate in the world's largest pharmaceutical and bio conference, 'CPHI Worldwide 2022,' held from the 1st to the 3rd (local time) at the Frankfurt International Exhibition Center in Germany.

This year's CPHI Worldwide 2022 is expected to be attended by over 2,500 companies and 45,000 industry professionals from more than 165 countries. Daewoong Pharmaceutical has consistently participated until 2019, just before the COVID-19 pandemic.

Daewoong Pharmaceutical plans to set up a solo booth and promote to existing and potential business partners. Along with the corporate brand, it will promote its key pipelines including its own research and development new drugs such as the gastroesophageal reflux disease treatment 'Pexuclu,' the diabetes new drug 'Envlo' (generic name Inavogliflozin) with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor mechanism, and the pulmonary fibrosis treatment 'DWN12088' with a prolyl-tRNA synthetase (PRS) inhibitor mechanism, as well as improved new drugs, generics, and stem cell therapies. The company will also promote technology import/export, joint development, and contract development and manufacturing organization (CDMO) businesses. The company stated that meetings are already scheduled with over 100 companies from the U.S., Europe, China, Latin America, India, the Middle East, and the Commonwealth of Independent States (CIS) regions.

Through this conference, Daewoong Pharmaceutical aims to advance negotiations with potential partner companies in regions where Pexuclu has not yet entered, such as the U.S., Latin America, India, and CIS, and expects to discover numerous new partners for Inavogliflozin, which is anticipated to receive domestic approval within the year. In fact, Daewoong Pharmaceutical discovered partners for Pexuclu in Latin America and the Middle East at CPHI 2019 and signed export contracts the following year.

Additionally, the company expects its globally established botulinum toxin (BTX) brand 'Nabota' to attract significant attention. It will also pursue new partnerships for the export of the idiopathic pulmonary fibrosis treatment 'DWN12088,' ulcerative colitis treatment 'BBT-401,' anticancer sustained-release injection 'Lupier Depot,' hair loss sustained-release injection 'IVL3001' (generic name Finasteride), and hyperlipidemia treatment 'Crezet.'

Furthermore, to expand its pipeline, Daewoong Pharmaceutical will promote technology import and joint development of new formulations, new technology pharmaceuticals, medical devices, and digital healthcare products. It will actively seek collaboration opportunities for contract manufacturing of stem cell therapies aimed at new business expansion.

Seungho Jeon, CEO of Daewoong Pharmaceutical, said, "Through participating in this CPHI, Daewoong Pharmaceutical aims to strengthen its overseas pharmaceutical and bio network after the COVID-19 pandemic and find partners to introduce our own research and development new drugs to overseas patients. We will accelerate our overseas market expansion by promoting our excellent R&D capabilities and new drug pipelines."

This content was produced with the assistance of AI translation services.